Abstract The new generation androgen receptor (AR) pathway inhibitor enzalutamide can prolong the survival of patients with metastatic prostate cancer. However, resistance to inevitably develops in these patients, and underlying mechanisms this are not fully defined. Here we demonstrate that kinesin family member 15 (KIF15) contributes by enhancing AR signaling cancer cells. KIF15 directly boun...

For several years, prostate cancer has remained the most common malignancy in male patients Poland. A large number of combined with rising costs therapy translate into a significant socio-economic burden. In clinical oncologist’s practice, we usually deal advanced cancer. Taking account poorer prognosis disease, development new therapeutic options as well their adequate selection is paramount i...

Major advances have been achieved recently in the treatment of metastatic castration-resistant prostate cancer, resulting in significant improvements in quality of life and survival with the use of several new agents, including the next-generation androgen receptor (AR)-targeted drugs abiraterone and enzalutamide. However, virtually all patients will eventually progress on these therapies and m...

Background . The addition of enzalutamide to standard androgen deprivation therapy (ADT) significantly increases overall survival and progression-free in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared ADT. Objective : evaluate the incremental cost/effectiveness ratio (ICER) use mHSPC ICER as first-line for castration-resistant (mCRPC) from Russian healthcare system ...

The treatment of advanced prostate cancer has been transformed by novel antiandrogen therapies such as enzalutamide. Here, we identify induction of glucocorticoid receptor (GR) expression as a common feature of drug-resistant tumors in a credentialed preclinical model, a finding also confirmed in patient samples. GR substituted for the androgen receptor (AR) to activate a similar but distinguis...

Despite the introduction of novel therapies that maximally decrease androgen-receptor (AR) signaling activity, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease. Even though abiraterone and enzalutamide represent breakthroughs in the treatment of mCRPC and have demonstrated significant survival benefits, a significant proportion of patients have primary resistance...

Recent advances in understanding the mechanisms underlying the development and progression of castration resistant prostate cancer from androgen-sensitive prostate cancer have provided new avenues exploring efficacious therapies in a disease which is the second leading cause of cancer deaths among men in the western world. In the evolution of second generation anti-androgens, enzalutamide, a no...

Castration-resistant prostate cancer is an incurable disease. To date, six agents-abiraterone, enzalutamide, docetaxel, cabazitaxel, radium-223 and sipuleucel-T- have shown clinical efficacy in phase III clinical trials, leading to their FDA approval. Patients are typically sequenced through most or all of these agents, and then eventually succumb to their disease. Development of new treatments...

Clinical resistance to the second-generation antiandrogen enzalutamide in castration-resistant prostate cancer (CRPC), despite persistent androgen receptor (AR) activity in tumors, highlights an unmet medical need for next-generation antagonists. We have identified and characterized tetra-aryl cyclobutanes (CBs) as a new class of competitive AR antagonists that exhibit a unique mechanism of act...